The PROFILE trials demonstrated that crizotinib, a first-in-class ALK TKI, achieves a significantly higher response in the systemic lesions of ALK+ NSCLC pts as compared with chemotherapy; however, it was not fully clarified whether crizotinib is effective for CNS metastasis [3–6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.